Volition Announces Detection of Over 95% of Early-Stage Cancers

Volition Announces Detection of Over 95% of Early-Stage Cancers Accessibility StatementSkip Navigation HENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture- Seqâ"¢ technology. Dr. Jake Micallef, Chief Scientific Officer, Volition, commented: Volition Announce ...